Merus Named BioCapital Europe 2017 Company of the Year
Award Recognizes Company’s Substantial Transformation and Breakthroughs Over Past 12 Months
UTRECHT, The Netherlands, March 16, 2017 (GLOBE NEWSWIRE)
— Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has been named BioCapital Europe’s Company of the Year for 2017. In its 15th consecutive year, BioCapital Europe, organized by Life Sciences Partners (LSP), is Europe’s premier life sciences investment conference. The Company of the Year Award is given to the organization that has undergone the most substantial transformation in the previous year and has experienced a breakthrough with respect to its technology, clinical development, partnering, IPO and/or M&A activities.
“This achievement is a significant honor for all of us at Merus and reflects the hard work we have put in to further advance our pipeline of bispecific antibody therapeutics aimed at substantially prolonging the lives of cancer patients,” said Ton Logtenberg, PhD, Chief Executive Officer of Merus. “Our lead candidates, MCLA-128 and MCLA-117, continue to advance in the clinic for potential treatments for HER2-expressing solid tumors and acute myeloid leukemia. Additionally, over the past year, we announced several important collaborations, most recently, a transformative, global research collaboration with Incyte Corporation to develop additional novel therapeutic candidates utilizing our proprietary Biclonics® technology platform. Merus is positioned for long-term success and being voted BioCapital Europe 2017 Company of the Year is recognition of that potential.”
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus’ second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Contacts: Media: Eliza Schleifstein +1 973 361 1546 firstname.lastname@example.org Investors: Kimberly Minarovich +1 646 368 8014 email@example.com